Trials / Completed
CompletedNCT00681941
An Open Label Dose Titration of Sevelamer Carbonate Tabs 3 Times a Day in Hyperphosphatemic CKD Patients Not On Dialysis
An Open Label, Dose Titration of Sevelamer Carbonate Tablets Dosed Three Times a Day in Hyperphosphatemic Chronic Kidney Disease Patients Not On Dialysis
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 49 (actual)
- Sponsor
- Genzyme, a Sanofi Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Approximately 45 hyperphosphatemic CKD patients not on dialysis will be entered into this study at approximately 20 sites within Europe and 5-10 in Australia. The purpose of this study is to determine if sevelamer carbonate tablets dosed three times a day (TID) is an effective treatment for the control of serum phosphorous levels in hyperphosphatemic CKD patients not on dialysis. Total length of participation is approximately 14 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sevelamer carbonate (Renvela®) | Sevelamer Carbonate Tablets Dosed Three Times A Day |
Timeline
- Start date
- 2006-01-01
- Primary completion
- 2007-01-01
- Completion
- 2007-03-01
- First posted
- 2008-05-21
- Last updated
- 2015-03-20
Locations
25 sites across 5 countries: Australia, Denmark, France, Germany, United Kingdom
Source: ClinicalTrials.gov record NCT00681941. Inclusion in this directory is not an endorsement.